Lord, Abbett & Co. LLC Tg Therapeutics, Inc. Transaction History

Lord, Abbett & Co. LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$7.81 - $20.45 $1.52 Million - $3.99 Million	-195,212 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$15.2 - $35.51 $17 Million - $39.7 Million	-1,118,576 Reduced 85.14%	195,212 $3.71 Million
Q3 2021 Nov 09, 2021	SELL	$21.78 - $40.45 $33 Million - $61.2 Million	-1,512,974 Reduced 53.52%	1,313,788 $43.7 Million
Q2 2021 Aug 11, 2021	SELL	$32.5 - $48.96 $60.7 Million - $91.5 Million	-1,868,539 Reduced 39.8%	2,826,762 $110 Million
Q1 2021 May 11, 2021	BUY	$41.61 - $54.3 $10.6 Million - $13.8 Million	254,842 Added 5.74%	4,695,301 $226 Million
Q4 2020 Feb 09, 2021	SELL	$25.27 - $54.9 $14.1 Million - $30.6 Million	-558,067 Reduced 11.16%	4,440,459 $231 Million
Q3 2020 Nov 12, 2020	BUY	$18.49 - $27.24 $67.9 Million - $100 Million	3,671,841 Added 276.77%	4,998,526 $134 Million
Q2 2020 Aug 14, 2020	BUY	$8.9 - $21.84 $3.39 Million - $8.32 Million	380,921 Added 40.28%	1,326,685 $25.8 Million
Q1 2020 May 14, 2020	BUY	$7.14 - $15.99 $6.75 Million - $15.1 Million	945,764 New	945,764 $9.31 Million

338

88.3M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.29B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.